U.S. markets open in 8 hours 13 minutes

iShares Nasdaq Biotechnology ETF (IBB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
159.65+2.72 (+1.73%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close156.93
Open158.86
Bid0.00 x 800
Ask0.00 x 1300
Day's Range158.37 - 160.01
52 Week Range92.15 - 174.04
Volume2,371,773
Avg. Volume2,769,466
Net Assets10.37B
NAV157.12
PE Ratio (TTM)N/A
Yield0.21%
YTD Daily Total Return3.79%
Beta (5Y Monthly)0.94
Expense Ratio (net)0.46%
Inception Date2001-02-05
  • MarketWatch

    Athenex stock plunges to pace all decliners after disappointing FDA response to breast cancer treatment NDA

    Shares of Athenex Inc. plummeted 54.6% on very active afternoon trading Monday, enough to be the biggest decliner listed on major U.S. exchanges, after the Food and Drug Administration said the biopharmaceutical company's New Drug Application (NDA) for its metastatic breast cancer treatment, oral paclitaxel plus encequidar, is not ready for approval in its present form. Trading volume spiked to 40.1 million shares, compared with the full-day average of about 1.1 million shares. The company said earlier that the FDA issued a complete response letter (CRL) expressing concerns of a safety risk to patients, and recommended a new clinical trial be conducted. Separately, the company reported a fourth-quarter net loss that widened to $49.5 million, or 53 cents a share, from $21.7 million, or 28 cents a share, in the year-ago period, wider than the FactSet consensus for a per-share loss of 44 cents. Revenue fell 36.5% to $21.8 million, topping the FactSet consensus of $20.7 million. The stock has lost 55.1% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has climbed 40.2% and the S&P 500 has advanced 32.4%.

  • MarketWatch

    Otonomy stock loses half its value after disappointing trial results of vertigo treatment

    Shares of Otonomy Inc. plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's disease (vertigo) treatment failed to meet its primary endpoint. "We are disappointed by the top-line results for the primary intent-to-treat population and are undertaking an assessment to understand the difference observed with the per protocol analysis," said Chief Executive David Weber. He said the company's focus turns to the "strong pipeline," highlighted by the "successful" clinical trial results of its tinnitus and hearing loss treatments, with clinical readouts anticipated in mid-2022. Weber said he expects the company's existing cash balance is enough to to achieve the clinical readouts. The stock has rallied 51.8% over the past 12 months through Friday, while the iShares Nasdaq Biotechnology ETF has advanced 35.1% and the S&P 500 has gained 17.1%.

  • MarketWatch

    Vaccinex's stock soars toward record gain on record volume after deals with 'prominent' drug makers

    Shares of Vaccinex Inc. soared toward a record rally on record volume Friday, after the biotechnology company announced the signing of multiple-project deals with two "prominent" pharmaceutical companies. The collaborations will focus on the use of Vaccinex's antibody discovery and novel viral display platform, ActivMAb, for antibody discovery. The names of the drug makers and the financial terms over the deals were not disclosed. The stock soared 119.9% in midday trading, making the stock the biggest gainer on major U.S. exchanges, even after paring an earlier gain of as much as 233.1%. Trading volume skyrocketed to 215.3 million shares, compared with the full-day average over the past 30 days of about 711,000 shares. Both the gain and the volume were the most for the stock since it went public in August 2018. It has now more than tripled (up 221.9%) over the past three months, while the iShares Nasdaq Biotechnology ETF has rallied 21.5% and the S&P 500 has gained 9.5%.